Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT)

Trial Profile

A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ezetimibe/simvastatin (Primary) ; Simvastatin
  • Indications Acute coronary syndromes; Cardiovascular disorders; Stroke; Unstable angina pectoris
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPROVE-IT
  • Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.; Schering-Plough
  • Most Recent Events

    • 12 Oct 2021 Results assessing the relationship between baseline LDL-C above and below 70 mg/dL and the benefit of adding ezetimibe to statin in patients post-acute coronary syndrome (ACS), published in the Journal of the American College of Cardiology.
    • 27 Aug 2019 Results assessing the role of established CV biomarkers in assessing likely benefit with Ezetimibe added to statin therapy in post-ACS patients in the biomarker substudy, published in the Journal of the American College of Cardiology
    • 25 Jan 2019 Results published in the American Journal of Cardiology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top